PATIENT-SAFETY-MOVEMENT
9.5.2018 16:32:11 CEST | Business Wire | Press release
The Australian and New Zealand College of Anaesthetists (ANZCA) is partnering with the Patient Safety Movement Foundation (PSMF) in support of the mission to eliminate medical errors within hospitals - the 14 th leading cause of death worldwide. The announcement was made publicly at ANZCA’s Annual Scientific Meeting (ASM) in Sydney on May 8, 2018. Dr. Michael A. E. Ramsay, Anaesthetist, and Patient Safety Movement Foundation Board Member was present to sign the Commitment to Action Letter publicly alongside ANZCA President, Professor David A. Scott.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20180509005874/en/
“We are thrilled to have the Australian and New Zealand College of Anaesthetists join us in our fight to eliminate preventable harm from hospitals. Through this partnership, we will reach the next generation of anaesthetists and recruit two important countries in our global effort to improve patient safety through the implementation of evidence-based processes,” explains Joe Kiani, Founder and Chairman of the Patient Safety Movement Foundation.
ANZCA runs one of Australasia’s largest specialist medical colleges and is the professional organisation representing nearly 6400 specialist anaesthetists and 1500 anaesthetists in training. ANZCA’s commitment represents the first by a major partner in Australia or New Zealand and joins 4,598 other committed hospitals and partners in 44 countries working towards the goal of eliminating preventable harm in hospitals.
“Patient harm and patient deaths occur in our hospitals daily, despite our best intentions. Many of these events are preventable if we apply existing knowledge, especially with the aid of new technologies. ANZCA welcomes this partnership which recognises our joint commitment to safety and quality in our specialty and improving patient safety,” said Professor Scott. “Initiatives such as this are so important for patients, hospitals and the specialty of anaesthesia.”
As a Committed Partner, ANZCA will work with the PSMF to improve patient outcomes with an acute focus on anesthesiology and perioperative care. Actions include:
| a. | Spreading the PSMF mission to ANZCA members; | |||
| b. | Identifying Actionable Patient Safety Solutions (APSS) that align with ANZCA’s standards and/or policies and inviting members working in hospitals to implement APSS or similar processes with the aim of eliminating preventable patient deaths in hospitals; | |||
| c. | Annually disseminating relevant APSS to ANZCA members; | |||
| d. | Engaging with the PSMF at its annual meetings to develop and improve relevant APSS. | |||
To learn more about the Patient Safety Movement Foundation, please visit www.patientsafetymovement.org .
About Patient Safety Movement Foundation: More than 200,000 people die every year in U.S. hospitals and 4.8 million worldwide in ways that could have been prevented. The Patient Safety Movement Foundation is a global non-profit which creates free tools for patients and hospitals. The Patient Safety Movement Foundation was established through the support of the Masimo Foundation for Ethics, Innovation, and Competition in Healthcare to reduce that number of preventable deaths to ZERO by 2020 (0X2020™). Improving patient safety will require a collaborative effort from all stakeholders, including patients, healthcare providers, medical technology companies, government, employers, and private payers. The Patient Safety Movement Foundation works with all stakeholders to address the problems with actionable solutions for patient safety. The Foundation also convenes the World Patient Safety, Science & Technology Summit. The Summit brings together some of the world’s best minds for thought-provoking discussions and new ideas to challenge the status quo. By presenting specific, high-impact solutions to meet patient safety challenges, called Actionable Patient Safety Solutions, encouraging medical technology companies to share the data their products are purchased for, and asking hospitals to make commitments to implement Actionable Patient Safety Solutions, the Patient Safety Movement Foundation is working toward ZERO preventable deaths by 2020. Visit patientsafetymovement.org.
About ANZCA: The Australian and New Zealand College of Anaesthetists (ANZCA) is the professional organisation for about 6400 specialist anaesthetists (Fellows) and 1500 anaesthetists in training (trainees). One of Australia's largest specialist medical colleges, ANZCA, along with its Faculty of Pain Medicine, is responsible for the training, examination and specialist accreditation of anaesthetists and pain medicine specialists and the standards of clinical practice in Australia and New Zealand. The College also plays a significant role in the advancement of anaesthesia in southeast Asia and South Pacific island countries.
View source version on businesswire.com: https://www.businesswire.com/news/home/20180509005874/en/
Contact:
Patient Safety Movement Foundation
Tanya Lyon, Public Relations
Manager
(949) 351-2858
tanya.lyon@patientsafetymovement.org
or
Australian
& New Zealand College of Anaesthetists
Carolyn Jones, Media
Manager
+61 3 8517 5303
cjones@anzca.edu.au
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Mobix Labs Signs Definitive Agreement to Acquire Vision Aerial, Accelerating Global Drone Platform for National Security and Aerial Intelligence24.7.2026 13:00:00 CEST | Press release
Transaction accelerates Mobix Labs’ global aerial intelligence strategy and National Security Matters Initiative Mobix Labs, Inc. (Nasdaq: MOBX) today announced that it has signed a definitive agreement to acquire Vision Aerial, Inc., a U.S.-based designer and manufacturer of American-built, National Defense Authorization Act (NDAA)-compliant unmanned aerial systems. The definitive agreement moves the transaction beyond the previously announced letter of intent and represents a major step toward closing an acquisition that would expand Mobix Labs into one of the world’s most important technology growth markets: secure drones, autonomous aerial systems and aerial intelligence for national security, critical infrastructure, energy, public safety, industrial inspection and government operations. Vision Aerial’s customers and end-users include the U.S. Air Force, U.S. Navy, government agencies, energy and utility operators, research institutions and other organizations requiring performanc
Enhertu® Plus Pertuzumab Recommended for Approval in the EU by CHMP as First-Line Treatment for Patients with HER2 Positive Metastatic Breast Cancer24.7.2026 13:00:00 CEST | Press release
Recommendation based on DESTINY-Breast09 phase 3 trial results that showed Enhertu plus pertuzumab reduced the risk of disease progression or death by 44% versus THP with a median progression-free survival exceeding three years If approved, Daiichi Sankyo and AstraZeneca’s Enhertu plus pertuzumab would become first new treatment in the EU in more than a decade for first-line HER2 positive metastatic breast cancer Enhertu® (trastuzumab deruxtecan) in combination with pertuzumab has been recommended for approval in the European Union (EU) for the first-line treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+ or in-situ hybridization [ISH]+) breast cancer. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP)
SLB Announces Second-Quarter 2026 Results24.7.2026 12:50:00 CEST | Press release
Revenue of $8.97 billion increased 3% sequentially and 5% year on year GAAP EPS of $0.52 increased 4% sequentially and decreased 30% year on year EPS, excluding charges and credits, of $0.55 increased 6% sequentially and decreased 26% year on year Net income attributable to SLB of $786 million increased 5% sequentially and decreased 22% year on year Adjusted EBITDA of $1.90 billion increased 7% sequentially and decreased 7% year on year Cash flow from operations was $1.36 billion and free cash flow was $716 million Board approved quarterly cash dividend of $0.295 per share SLB (NYSE: SLB) today announced results for the second-quarter 2026. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260722694386/en/ The exterior of the SLB headquarters in Houston, Texas.Second-Quarter Results(Stated in millions, except per share amounts)Three Months EndedChangeJun. 30, 2026Mar. 31, 2026Jun. 30, 2025SequentialYear-on-yearRevenue $8,972 $8
NIQ Expands GenAI Capabilities Across gfknewron, Turning Trusted Intelligence into Decisions Faster24.7.2026 12:30:00 CEST | Press release
New capabilities help businesses uncover trends faster, simplify complex analysis, and accelerate confident decision-making NIQ (NYSE: NIQ), a leader in consumer intelligence, today announced the expansion of AI-powered Smart Insights across its gfknewron® platform. By bringing together markets and categories into a single view, gfknewron enables businesses to transform complex market, consumer and supply chain data into clear, actionable intelligence quickly. The latest enhancements help users identify trends, opportunities and performance drivers more quickly, reducing the time required to analyze large datasets and accelerating confident decision-making across teams. As brands and retailers face growing pressure to respond quickly to changing consumer behavior and market dynamics, the ability to unlock meaningful insights from increasingly rich datasets has become a significant competitive advantage. As AI is only as effective as the intelligence behind it, Smart Insights helps busi
Thales to Strengthen Romania’s Airspace Protection With Twelve Ground Master 200 MM/A Radars24.7.2026 10:05:00 CEST | Press release
The Romanian General Directorate for Armaments and the French Direction Générale de l’Armement (DGA – the French defence procurement agency) have signed an agreement to supply twelve Thales GM200 Multi-Mission All-in-one (GM200 MM/A) radars to protect the Romanian airspace. This government-to-government agreement underlines the high level of partnership between France and Romania, within the framework of the European Union’s SAFE funding programme, in order to bolster Europe’s defence capabilities. The GM200 MM/A is part of Thales’ proven Ground Master radar family, which has already been deployed in over 40 countries, including now in Romania. In a context of growing collaboration between European nations to bolster collective security, the Romanian General Directorate for Armaments has just signed a landmark agreement with France’s Direction Générale de l’Armement (DGA) to acquire twelve Thales Ground Master 200 Multi-Mission All-in-one (GM200 MM/A) radars. This government-to-governm
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
